A new blood test has been introduced in Australia, enabling earlier detection of Alzheimer's disease. This advancement aims to provide individuals with more time to plan and seek appropriate care.
The test, known as Elecsys® pTau217, measures specific proteins in the blood that indicate the presence of amyloid plaques in the brain—a hallmark of Alzheimer's disease. Developed by Roche in collaboration with Eli Lilly and Company, it received the CE mark in May 2026, signifying its approval for use in Europe.
In Australia, the test became available in November 2025, marking a significant step in Alzheimer's diagnostics. Prior to this, diagnosing Alzheimer's often involved invasive procedures like lumbar punctures or costly PET scans. The new blood test offers a less invasive and more accessible alternative, potentially reducing the time to diagnosis and allowing for earlier intervention.
The introduction of this test is particularly timely, as treatments for Alzheimer's disease are becoming more accessible. Early detection can help individuals and their families make informed decisions about care and treatment options. However, it's important to note that while the test can indicate the presence of amyloid plaques, it does not confirm the onset of Alzheimer's disease. Further clinical evaluations are necessary to establish a definitive diagnosis.
As the test becomes more widely available, healthcare providers and patients will need to consider how to integrate this tool into existing diagnostic pathways. Ongoing research and clinical studies will continue to refine its accuracy and utility, ensuring it becomes a valuable component in the fight against Alzheimer's disease.